TESARO Inc (NASDAQ:TSRO) – Gabelli reduced their FY2018 EPS estimates for shares of TESARO in a research note issued on Wednesday, Zacks Investment Research reports. Gabelli analyst J. He now expects that the biopharmaceutical company will earn ($8.75) per share for the year, down from their prior estimate of ($5.10). Gabelli also issued estimates for TESARO’s FY2019 earnings at ($4.90) EPS, FY2020 earnings at ($3.20) EPS, FY2021 earnings at ($1.00) EPS and FY2022 earnings at $0.15 EPS.
A number of other research analysts also recently issued reports on TSRO. BidaskClub upgraded TESARO from a “sell” rating to a “hold” rating in a report on Tuesday. Morgan Stanley reduced their price target on TESARO from $156.00 to $146.00 and set an “overweight” rating on the stock in a report on Thursday, March 1st. ValuEngine upgraded TESARO from a “sell” rating to a “hold” rating in a report on Friday, March 2nd. Credit Suisse Group reiterated an “in-line” rating and set a $141.00 target price (down previously from $150.00) on shares of TESARO in a report on Wednesday, February 28th. Finally, Wells Fargo & Co reiterated an “outperform” rating and set a $122.00 target price (down previously from $224.00) on shares of TESARO in a report on Wednesday, February 28th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. TESARO presently has an average rating of “Buy” and a consensus price target of $133.39.
Shares of TESARO (TSRO) traded down $1.91 during trading hours on Monday, reaching $62.69. The company had a trading volume of 819,305 shares, compared to its average volume of 1,245,091. TESARO has a 52 week low of $52.20 and a 52 week high of $168.92. The stock has a market cap of $3,410.00, a P/E ratio of -6.83 and a beta of 1.40. The company has a debt-to-equity ratio of 1.75, a quick ratio of 4.39 and a current ratio of 4.74.
TESARO (NASDAQ:TSRO) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.96). TESARO had a negative net margin of 222.15% and a negative return on equity of 126.44%. The business had revenue of $48.02 million for the quarter, compared to analysts’ expectations of $51.78 million.
In related news, VP Grant C. Bogle sold 1,809 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $54.85, for a total value of $99,223.65. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Mary Lynne Hedley sold 3,855 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $54.86, for a total value of $211,485.30. Following the completion of the transaction, the chief operating officer now directly owns 16,073 shares in the company, valued at $881,764.78. The disclosure for this sale can be found here. Over the last ninety days, insiders purchased 334,913 shares of company stock worth $19,083,294 and sold 13,042 shares worth $760,526. Corporate insiders own 34.60% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in TESARO by 5.6% in the 4th quarter. BlackRock Inc. now owns 4,067,066 shares of the biopharmaceutical company’s stock valued at $337,039,000 after acquiring an additional 213,920 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of TESARO by 24.9% during the 3rd quarter. Janus Henderson Group PLC now owns 895,556 shares of the biopharmaceutical company’s stock valued at $115,616,000 after buying an additional 178,406 shares during the period. TimesSquare Capital Management LLC lifted its holdings in shares of TESARO by 226.1% during the 4th quarter. TimesSquare Capital Management LLC now owns 856,600 shares of the biopharmaceutical company’s stock valued at $70,986,000 after buying an additional 593,924 shares during the period. Rock Springs Capital Management LP lifted its holdings in shares of TESARO by 10.8% during the 4th quarter. Rock Springs Capital Management LP now owns 548,500 shares of the biopharmaceutical company’s stock valued at $45,454,000 after buying an additional 53,250 shares during the period. Finally, Alliancebernstein L.P. lifted its holdings in shares of TESARO by 16.9% during the 4th quarter. Alliancebernstein L.P. now owns 513,542 shares of the biopharmaceutical company’s stock valued at $42,557,000 after buying an additional 74,290 shares during the period.
TRADEMARK VIOLATION NOTICE: This story was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://ledgergazette.com/2018/03/14/gabelli-analysts-reduce-earnings-estimates-for-tesaro-inc-tsro.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.